Authors' response re. “May Silymarin be selectively considered for nonalcoholic fatty liver disease without elevated transaminases?”

[...]no safe conclusions could be drawn, and additional, better-designed studies are needed before silymarin could be recommended for the management of hyperlipidemia and DM. With regard to statins, their use in patients with increased cardiovascular risk and hyperlipidemia or DM is encouraged [10] despite the existence of chronic liver disease, as patients suffering from chronic liver disease have been shown to not be at a higher risk of statin-induced liver injury [11]. [...]silymarin, which is the bioactive component of milk thistle, is a herb that has been studied as a possible hepatoprotective agent in different liver diseases.